...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based cardiovascular medicine >Commentary
【24h】

Commentary

机译：评论

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Restenosis limits the long-term success of coronary angioplasty, leading to repeat revascularisation. Restenotic mechanisms are most active during the first months after percutaneous coronary intervention. Oral drug treatment during this period may reduce restenosis and subsequent re-angioplasty at relatively low cost. This well powered study compared verapamil with placebo for people with a moderate risk of restenosis in a de-novo lesion in a native coronary artery. There was a trend towards a greater incidence of target vessel revascularisation in people with restenosis in the placebo group compared with verapamil (p = 0.06). However, there were no significant differences in the more sensitive parameters of quantitative coronary angiography at follow-up. The difference in late loss at follow-up was only 0.07 mm, and in diameter stenosis, 4.7%.
机译：再狭窄限制了冠状动脉血管成形术的长期成功，导致重复血运重建。经皮冠状动脉介入治疗后的头几个月，再狭窄机制最为活跃。在此期间的口服药物治疗可以以相对较低的成本减少再狭窄和随后的血管成形术。这项功能强大的研究将维拉帕米与安慰剂用于天然冠状动脉新生病变中再狭窄风险中等的人群。与维拉帕米相比，安慰剂组再狭窄患者中靶血管血运重建的发生率有增加的趋势（p = 0.06）。但是，随访时定量冠状动脉造影的更敏感参数没有显着差异。随访中晚期丢失的差异仅为0.07 mm，直径狭窄的差异为4.7％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号